LA JOLLA, CA – May 12, 2025 – In a discovery poised to revolutionize the treatment of a wide array of debilitating metabolic disorders, scientists at the Salk Institute have identified a crucial role for estrogen-related receptors (ERRs) in regulating energy metabolism and combating muscle fatigue. A new study, published today in the prestigious Proceedings of the National Academy of Sciences, pinpoints these often-overlooked proteins as potentially indispensable drivers of mitochondrial function, offering a novel and direct therapeutic pathway for conditions ranging from muscular dystrophy to age-related decline.
The groundbreaking research suggests that by targeting and boosting the activity of estrogen-related receptors, scientists could develop drugs capable of restoring cellular energy supplies, thereby alleviating muscle weakness and fatigue in millions of people afflicted by metabolic dysfunction. This finding represents a significant leap forward in understanding and potentially treating a complex group of diseases that currently lack effective pharmacological interventions.
The Ubiquitous Role of Mitochondria: Cellular Powerhouses Under Threat
At the heart of this discovery lies the fundamental biological process of cellular energy production. Throughout our bodies, every cell relies on microscopic, bean-shaped structures known as mitochondria. Often dubbed the "powerhouses of the cell," mitochondria are responsible for converting the food we eat into adenosine triphosphate (ATP), the primary energy currency that fuels virtually all cellular activities. This cellular-level metabolism is particularly vital in tissues with high energy demands, such as muscle cells, which require a substantial and constant supply of fuel to power movement, contraction, and recovery. The heart, brain, and other vital organs also depend heavily on robust mitochondrial function to sustain their complex operations.
However, this delicate energy system is vulnerable to dysfunction. Mitochondria can become compromised due to a variety of factors, leading to a cascade of health problems. Tragically, approximately 1 in 5,000 individuals are born with inherited mitochondrial diseases, genetic disorders that can severely impair energy production from birth, often leading to multi-systemic failure, developmental delays, and profound muscle weakness. Beyond these congenital conditions, a far greater number of people develop metabolic dysfunction later in life. This acquired form of mitochondrial impairment is strongly associated with the natural process of aging, contributing to age-related muscle loss (sarcopenia) and cognitive decline.
Furthermore, mitochondrial dysfunction is a recognized hallmark and contributing factor in the progression of numerous chronic and debilitating diseases. It plays a role in the metabolic shifts seen in certain cancers, contributes to the severe fatigue experienced by patients with multiple sclerosis (MS), exacerbates the decline in heart function in various forms of heart disease, and is increasingly implicated in neurodegenerative conditions like Alzheimer’s disease and other forms of dementia. The pervasive nature of mitochondrial dysfunction across such a broad spectrum of human ailments underscores the urgent need for effective therapeutic strategies. Despite decades of research, treating these complex conditions by directly addressing mitochondrial health has remained an elusive goal, often limited by the complexity of cellular regulation and the challenges of drug delivery.
Unveiling Estrogen-Related Receptors: A Historical Perspective
The current breakthrough builds upon a rich history of scientific inquiry at the Salk Institute, particularly the pioneering work of senior author Dr. Ronald Evans. Dr. Evans, a professor and the March of Dimes Chair in Molecular and Developmental Biology at Salk, is a towering figure in the field of molecular biology, renowned for his landmark discovery in the 1980s of a family of proteins he named "nuclear hormone receptors." These receptors are a class of proteins found within cells that are activated by steroid and thyroid hormones, as well as other lipid-soluble signals. Upon activation, these hormone-activated receptors attach themselves directly to specific sequences of our DNA, acting as molecular switches that control which genes get turned "on" or "off," thereby orchestrating a vast array of biological processes, from development and metabolism to reproduction and immunity.
Estrogen-related receptors (ERRs) represent a distinct branch within this expansive family of nuclear hormone receptors. Dr. Evans’ lab was instrumental in the initial discovery of estrogen-related receptors in 1988, and his team was among the very first to recognize their potential, albeit then largely uncharacterized, role in energy metabolism. For many years, ERRs remained somewhat enigmatic, often overshadowed by their more extensively studied cousins, the classic estrogen receptors. While ERRs structurally resemble classic estrogen receptors, they do not bind to or are activated by estrogen itself, suggesting a unique and independent set of biological functions. This distinction is crucial, as it implies that targeting ERRs could offer therapeutic benefits without the hormonal side effects associated with classical estrogen receptor modulation.
"Estrogen-related receptors look a lot like classic estrogen receptors, but their function has been much less understood," Dr. Evans explained. "Our lab discovered estrogen-related receptors in 1988 and was one of the first to recognize their role in energy metabolism. Now we’ve learned that estrogen-related receptors are indispensable drivers of mitochondrial growth and activity in our muscles. This makes them a really promising target to treat muscle weakness and fatigue in many different diseases that involve metabolic dysfunction." This long arc of research, spanning several decades, underscores the persistent dedication required to unravel fundamental biological mysteries and translate them into potential medical solutions.
The initial observations that ERRs are often found in parts of the body that demand a high supply of fuel to function, such as the heart and brain, naturally inspired Dr. Evans’ team to delve deeper into their potential regulatory role in another high-energy organ: skeletal muscle. The logical extension of this inquiry was to investigate how ERRs might govern the energetic demands of muscle tissue, especially during periods of increased activity.
The Muscle-Mitochondria Connection: Exercise and Energy Demand
Skeletal muscles, the engines of our movement, are exceptionally metabolically active tissues. They require a prodigious amount of energy to contract, relax, and maintain posture, with their fuel demands escalating dramatically during physical activity. When we exercise, our muscles experience an immediate surge in energy consumption. To meet this heightened demand, muscle cells initiate a remarkable adaptive process known as mitochondrial biogenesis. This intricate biological mechanism involves the cell increasing both the number and the overall mass of its mitochondria, essentially building more "energy factories" to produce more fuel. This adaptive response is a cornerstone of physical fitness, enhancing endurance and muscle performance.
However, herein lies a critical paradox and a major challenge for patient populations. While exercise is the most potent natural stimulus for mitochondrial biogenesis and improved muscle health, it is precisely what many individuals with muscular and metabolic disorders struggle to do, or cannot do at all. For patients suffering from conditions like muscular dystrophy, chronic fatigue syndrome, or severe heart failure, engaging in even moderate physical activity can be excruciatingly difficult, if not impossible. This creates a vicious cycle: compromised muscles lead to an inability to exercise, which in turn prevents the natural mitochondrial adaptation that could improve muscle function. Consequently, scientists have been intensely searching for alternative, pharmacological ways to stimulate this vital process of mitochondrial biogenesis, aiming to confer the benefits of exercise without the physical exertion.
"Mitochondria are our cells’ energy factories, so the more we exercise, the more mitochondria our muscles need," says first author Weiwei Fan, a staff scientist in Evans’ lab, articulating the core problem the research sought to address. "This got us thinking — if we could understand how exercise induces mitochondrial biogenesis, we might be able to target those same mechanisms pharmacologically to trigger this process in people who are too weak to exercise." This aspiration to "exercise in a pill" has long been a holy grail for researchers in metabolic health, and the current findings bring this goal considerably closer to reality.
Deconstructing the ERR Family: Alpha, Beta, and Gamma
To systematically investigate whether estrogen-related receptors indeed played a pivotal role in muscle cell metabolism, Dr. Fan and his colleagues embarked on a series of meticulously designed experiments using sophisticated genetic models. Their approach involved creating knockout mice, genetically engineered to lack specific forms of the estrogen-related receptors within their muscle tissues. The ERR family consists of three distinct forms: alpha (ERRα), beta (ERRβ), and gamma (ERRγ). By selectively deleting these different receptor types, the researchers could precisely examine the resulting effects on mitochondrial function and muscle health.
Their initial findings revealed a complex and nuanced interplay among the ERR subtypes. They observed that ERRα was by far the most abundant type of estrogen-related receptor present in muscle tissue. However, surprisingly, the loss of just this single, most prevalent receptor had only mild impacts on muscle tissue under normal, resting conditions. This suggested that while ERRα was abundant, other compensatory mechanisms might be at play when the muscle was not under stress.
Further investigation uncovered one such critical compensatory mechanism. The researchers discovered that ERRγ, despite making up only a small fraction – approximately 4% – of the total estrogen-related receptors, was able to effectively compensate for the absence of ERRα under normal metabolic conditions. This remarkable adaptability highlights the inherent robustness and redundancy built into biological systems, ensuring that vital functions can be maintained even when one component is compromised.
The true severity of the receptors’ importance became apparent when both ERRα and ERRγ were simultaneously deleted. This combined knockout led to "serious impairments" in muscle mitochondrial activity, shape, and size. Without the combined action of these two key players, the muscle cells’ energy factories were severely compromised, unable to function efficiently or maintain their structural integrity. This result strongly indicated that while ERRγ could compensate for ERRα in normal states, both were ultimately indispensable for optimal mitochondrial health and function. The precise role of ERRβ, though present, was not as prominently highlighted in this study’s core findings regarding exercise-induced biogenesis, suggesting a more specialized or less dominant role in this particular context.
The Exercise Revelation: ERR Alpha as the Indispensable Driver
While the initial studies elucidated the basal roles of ERRs, the team hypothesized that the seemingly "excess" abundance of the alpha-type estrogen-related receptor (ERRα) might be specifically geared towards helping muscles adapt and grow in response to physiological stress, particularly exercise. To test this hypothesis, the researchers introduced an exercise component into their mouse model. They had their genetically modified mice exercise on mechanical wheels, a controlled method to induce physical exertion and trigger mitochondrial biogenesis. This experimental setup allowed the researchers to precisely assess whether ERRα was indeed involved in the complex process of exercise-induced mitochondrial growth.
The results of this exercise experiment were stark and unequivocal. The loss of ERRα alone, which had shown only mild effects under resting conditions, was found to entirely block exercise-induced mitochondrial biogenesis. This pivotal finding transformed ERRα from a receptor with a seemingly redundant role to an indispensable driver under conditions of metabolic demand. It confirmed Dr. Evans’ earlier assertion that ERRs are "indispensable drivers of mitochondrial growth and activity in our muscles," particularly when the body is challenged to adapt and strengthen. This revelation positioned ERRα as a central figure in the muscle’s adaptive response to physical activity, making it a highly attractive target for therapeutic intervention.
Navigating the Therapeutic Landscape: PGC1 Alpha vs. ERR Alpha
For many years, the scientific community has recognized another protein, PGC1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), as a "master regulator" of mitochondria throughout the body. Previous studies had firmly established PGC1α’s critical role in driving exercise-induced mitochondrial growth and biogenesis. However, despite its powerful regulatory capabilities, PGC1α presents a significant challenge for therapeutic drug development. The issue stems from its mechanism of action: PGC1α cannot bind directly to genes to turn them "on" or "off." Instead, it functions as a coactivator, meaning it relies on partnering with other proteins, often nuclear hormone receptors, to get the job done. This indirect action makes PGC1α a more difficult target for pharmacological modulation, as developing drugs that effectively and specifically modulate its coactivator function without undesirable off-target effects has proven exceptionally complex.
The Salk team’s new findings elegantly resolved this therapeutic bottleneck. When Dr. Evans’ lab meticulously examined the muscle cells after exercise, they uncovered the crucial partnership: PGC1α was indeed collaborating with ERRα to drive the process of mitochondrial biogenesis. This was the missing piece of the puzzle. Crucially, unlike PGC1α, ERRα possesses the inherent ability to bind directly to mitochondrial energetic genes and activate their expression, effectively turning them "on." This direct gene-binding capability makes ERRα an exceptionally promising target for improving muscle’s mitochondrial performance.
The ability of a therapeutic agent to directly interact with a receptor that, in turn, directly binds to DNA and controls gene expression offers several advantages for drug development. It suggests a more specific and potentially more potent mechanism of action, reducing the likelihood of off-target effects and providing a clearer pathway for pharmacological intervention. By activating ERRα, scientists could potentially bypass the complexities of PGC1α’s indirect mechanisms, offering a more direct and effective way to stimulate mitochondrial growth and enhance energy production in muscle cells.
Broadening Horizons: Systemic Implications and Future Directions
The implications of this discovery extend far beyond the realm of muscle fatigue and muscular dystrophy. As Dr. Fan succinctly articulated, "Our findings suggest that activating estrogen-related receptors could not only help fuel people’s muscles, but it could also have other beneficial effects across the whole body." Improving mitochondrial function and energy metabolism is a foundational principle for cellular health, and its enhancement could indeed strengthen numerous different organ systems, particularly those with high energy demands.
- Brain Health: The brain is an extraordinarily energy-intensive organ. Enhanced mitochondrial function could have profound implications for cognitive function, potentially mitigating age-related cognitive decline and offering new avenues for treating neurodegenerative diseases like Alzheimer’s, Parkinson’s, and the cognitive and fatigue symptoms associated with multiple sclerosis. By ensuring a robust energy supply, brain cells might be better equipped to repair damage, maintain neuronal networks, and resist degenerative processes.
- Heart Disease: The heart is a tireless pump, constantly working and requiring immense amounts of ATP. Mitochondrial dysfunction is a known contributor to various forms of heart failure and cardiomyopathy. Activating ERRs could potentially improve the heart’s energetic efficiency, bolstering its pumping capacity and offering a novel therapeutic strategy for cardiovascular diseases.
- Aging and Sarcopenia: As we age, mitochondrial function naturally declines, contributing to sarcopenia (age-related muscle loss) and general frailty. An ERR-activating drug could potentially combat these effects, helping older adults maintain muscle mass, strength, and overall vitality, thereby improving their quality of life and independence.
- Metabolic Syndrome and Type 2 Diabetes: Impaired mitochondrial function is also implicated in insulin resistance and the development of type 2 diabetes. By improving energy metabolism, ERR activation could contribute to better glucose utilization and potentially offer a new approach to managing these widespread metabolic conditions.
- Chronic Fatigue Syndromes: For individuals suffering from chronic fatigue syndrome (CFS) or post-viral fatigue, where mitochondrial dysfunction is often suspected, ERR activators could offer a desperately needed therapeutic option to restore energy levels and alleviate debilitating exhaustion.
While the promise is immense, the journey from discovery to clinical application is long and complex. Future research will be critical in several key areas. Further investigation into the intricate functions and regulatory mechanisms of both alpha- and gamma-type receptors, and even the less-explored beta-type, will be essential to fully understand their individual and synergistic roles. This deeper understanding may lead to the identification of other potential therapeutic targets within the ERR network. Crucially, translational research will involve developing and testing specific ERR-activating compounds, first in preclinical models, and then, if successful, moving towards human clinical trials. Challenges will include ensuring the specificity of any new drug, minimizing potential off-target effects, and establishing long-term safety profiles.
Official Recognition and Collaborative Endeavors
The enthusiasm surrounding these findings is palpable among the scientific community, reflecting the potential paradigm shift this research could initiate. Dr. Ronald Evans and Dr. Weiwei Fan’s articulate explanations underscore not only the scientific rigor of their work but also their profound commitment to translating fundamental discoveries into tangible health benefits.
This monumental achievement is also a testament to the collaborative spirit inherent in modern scientific research. The study involved a dedicated team of researchers from the Salk Institute, including Hui Wang, Lillian Crossley, Mingxiao He, Hunter Robbins, Chandra Koopari, Yang Dai, Morgan Truitt, Ruth Yu, Annette Atkins, and Michael Downes. The collaboration extended beyond Salk, with contributions from Tae Gyu Oh of Salk and the University of Oklahoma, and Christopher Liddle of the University of Sydney, Australia. Such inter-institutional and international partnerships are increasingly vital for tackling complex biological questions.
Furthermore, the groundbreaking nature of this work was made possible by the unwavering support from a diverse array of funding bodies. Major contributions came from the National Institutes of Health (NIH) through multiple grants (P01HL147835, DK057978, DK120515, 1R21OD030076, CCSG P30CA23100, CCSG P30 CA014195, CCSG P30 CA014195, P30 AG068635), demonstrating the NIH’s commitment to foundational biomedical research. Additional critical support was provided by the Department of the Navy (N00014-16-1-3159), the Larry L. Hillblom Foundation, Inc. (2021-D-001-NET), the Wu Tsai Human Performance Alliance, the Henry L. Guenther Foundation, and the Waitt Foundation. This broad spectrum of public and private funding highlights the widespread recognition of the potential impact of this research on human health and well-being.
Conclusion: A New Era for Metabolic Health
The Salk Institute’s latest research marks a pivotal moment in our understanding of cellular energy metabolism. By unequivocally establishing estrogen-related receptors as direct and indispensable regulators of mitochondrial biogenesis and function in muscle, particularly during periods of metabolic demand, Dr. Evans’ team has unveiled a powerful new therapeutic target. The ability of ERRα to directly bind to and activate mitochondrial energetic genes offers a clear and actionable pathway for drug development, circumventing the complexities associated with other metabolic regulators.
This discovery holds immense promise for millions of individuals worldwide who suffer from a spectrum of conditions characterized by muscle weakness, fatigue, and systemic energy deficits. From inherited muscular dystrophies to the pervasive effects of aging and chronic diseases affecting the heart and brain, the potential to restore and enhance mitochondrial function through ERR activation could usher in a new era of metabolic health. As future research delves deeper into the intricacies of these receptors and moves towards clinical translation, the hope for improved quality of life, greater vitality, and more effective treatments for debilitating diseases grows ever stronger. The journey is ongoing, but the path forward has been illuminated with remarkable clarity.
About the Author
